Compared to the control group, median CSF GFAP and UCHL1 concentrations were significantly higher among all patients groups compared to controls, p < 0.001, respectively, Table 1., Fig. 1A, B. There was no difference in the CSF concentrations of either molecule between the MS and PN patients. This evidence concerns the gene GFAP and myeloid sarcoma.